Travere swings to $52.3M loss despite Q3 revenue jump
Alpha Vantage · Stock Titan · · AI-summarised by FinFlash
Travere Therapeutics posted a Q3 2026 net loss of $52.3 million, reversing net income of $25.7 million a year earlier, even as total revenue rose to $224.6 million from Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.Understand the context